The poor water solubility of drugs limits their oral bioavailability (BA) and presents challenges in the development of oral solid dosage forms. This issue is especially prevalent among new drug candidates, with approximately 40% of marketed drugs and 90% of new chemical entities exhibiting poor water solubility. However, there is no universal technique for formulating these drugs. Formulation studies using commercially established approaches to improve the dissolution and thus bioavailability of these drugs are desirable for the pharmaceutical industry to expedite the development stage.